Accessibility Menu
Arrow-Thin-Down
S&P 500
6,699.40
-0.5%
-35.95
Arrow-Thin-Down
DJI
46,590.41
-0.7%
-334.33
Arrow-Thin-Down
NASDAQ
22,740.40
-0.9%
-213.27
Arrow-Thin-Down
Bitcoin
$109,388
+1.4%
+$1,477.57
Arrow-Thin-Down
AAPL
$258.4
-1.7%
-$4.37
Arrow-Thin-Down
AMZN
$217.92
-1.9%
-$4.11
Arrow-Thin-Down
GOOG
$252.53
+0.5%
+$1.19
Arrow-Thin-Down
META
$733.46
+0.0%
+$0.19
Arrow-Thin-Down
MSFT
$520.63
+0.6%
+$2.97
Arrow-Thin-Down
NVDA
$180.05
-0.6%
-$1.12
Arrow-Thin-Down
TSLA
$438.89
-0.8%
-$3.72
Daily Stock GainersDaily Stock LosersMost Active Stocks
Cytokinetics Stock Quote

Cytokinetics (NASDAQ: CYTK)

$54.76
(-5.2%)
-3.02
Price as of October 22, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$54.76
Daily Change
(-5.2%) $3.02
Day's Range
$54.46 - $57.78
Previous Close
$54.76
Open
$57.78
Beta
1.02
Volume
3
Average Volume
2,181,021
Sector
Health Care
Market Cap
6.6B
Market Cap / Employee
$54.76M
52wk Range
$29.31 - $63.86
Revenue
-
Gross Margin
0.89%
Dividend Yield
N/A
EPS
-$5.12
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Cytokinetics Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
CYTK-0.33%+234.11%+27.28%-40%
S&P+14.5%+93.32%+14.09%+501%

Cytokinetics Company Info

Cytokinetics is a biopharmaceutical company focused on developing small-molecule therapeutics for the treatment of cardiovascular diseases and cancer.

News & Analysis

Featured Article

CYTK Earnings Jump 3,065%

Motley Fool Markets Team  |  Aug 7, 2025
Featured Article

Why Cytokinetics Stock Was a Nearly 5% Winner Today

Eric Volkman  |  Dec 20, 2024

Financial Health

General

Q2 2025YOY Change
Revenue$66.77M26714.9%
Gross Profit$64.48M3089.5%
Gross Margin96.58%962.8%
Market Cap$3.95B-36.5%
Market Cap / Employee$7.92M0.0%
Employees49817.7%
Net Income-$134.37M6.2%
EBITDA-$109.22M14.5%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$76.55M-59.8%
Accounts Receivable$8.41M0.0%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$824.07M8.4%
Short Term Debt$33.99M13.2%

Ratios

Q2 2025YOY Change
Return On Assets-44.10%3.2%
Return On Invested Capital-80.98%1.3%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$132.38M-30.8%
Operating Free Cash Flow-$128.24M-29.1%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book-447.46-398.64-35.09-14.793.18%
Price to Sales1930.34300.65247.8146.03-97.56%
Price to Tangible Book Value-447.45-398.64-35.09-14.793.18%
Enterprise Value to EBITDA-43.29-38.54-30.10-36.12-18.34%
Total Debt$789.63M$788.68M$791.06M$858.06M8.59%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services